A Value-Based Medicine Comparison of Interventions for Subfoveal Neovascular Macular Degeneration

Ophthalmology

Volumn 114, Issue 6, 2007, Pages 1170-1178

  Brown, Gary C ^a,b,c,d   Brown, Melissa M ^a,c,d,e   Brown, Heidi C ^a   Kindermann, Sylvia ^a   Sharma, Sanjay ^a,c,f  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c Eye Research Institute   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Queens Medical College   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB;

ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ENDOPHTHALMITIS; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MEDICARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL DISORDER; VITREOUS HEMORRHAGE;

APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; EVIDENCE-BASED MEDICINE; FOVEA CENTRALIS; HEALTH CARE COSTS; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; VISUAL ACUITY;

EID: 34247248392     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.09.019     Document Type: Article

References (35)

1. Arias E. United States life tables, 2002. Natl Vital Stat Rep 53 (2004) 1-38
2. Klein R., Klein B.E., Tomany S.C., et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 109 (2002) 1767-1779
3. Brown G.C., Sharma S., Brown M.M., and Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 118 (2000) 47-51
4. Brown M.M., Brown G.C., Stein J.D., et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 40 (2005) 277-287
5. Brown M.M., Brown G.C., Sharma S., et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc 103 (2005) 173-184
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1220-1231
7. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 111 (1993) 1200-1209
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch Ophthalmol 120 (2002) 1307-1314
10. Brown G.C., Brown M.M., Campanella J., and Beauchamp G.R. The cost-utility of photodynamic therapy in eyes with neovascular age-related macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 140 (2005) 679-687
11. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
12. Macugen (pegaptanib sodium injection) (2006), Eyetech Pharmaceuticals, New York. http://www.pfizer.com/pfizer/download/uspi_macugen.pdf Available at: http://www.pfizer.com/pfizer/download/uspi_macugen.pdf. Accessed July 11, 2005
13. Brown M.M., Brown G.C., Sharma S., and Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol 48 (2003) 204-223
14. Brown M.M., Brown G.C., and Sharma S. Evidence-Based to Value-Based Medicine (2005), AMA Press, Chicago 125-266
15. Olsen T.W., Feng X., Kasper T.J., et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 111 (2004) 250-255
16. Sharma S., Brown G.C., Brown M.M., et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 86 (2002) 493-496
17. Landy J., Stein J., Brown M.M., et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 8 (2002) 543-548
18. Brown G.C., Brown M.M., and Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 35 (2000) 127-133
19. Stein J.D., Brown G.C., Brown M.M., et al. The quality of life of patients with hypertension. J Clin Hypertens (Greenwich) 4 (2002) 181-188
20. Brown G.C., Brown M.M., Sharma S., et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 14 (2000) 18-24
21. Brown M.M., Brown G.C., Sharma S., et al. Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol 86 (2002) 8-11
22. Brown G.C., Brown M.M., Sharma S., et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 99 (2001) 199-203
23. Brown M.M., Brown G.C., Sharma S., et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 85 (2001) 327-331
24. Brown G.C. Vision and quality-of-life. Trans Am Ophthalmol Soc 97 (1999) 473-511
25. Brown M.M., Brown G.C., Sharma S., et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 120 (2002) 481-484
26. Brown M.M., Brown G.C., Sharma S., and Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 128 (1999) 324-0
27. Centers for Medicare & Medicaid Services. Medicare fee schedule. Available at: http://www.cms.hhs.gov/apps/ama/license.asp?file=/physicianfeesched/downloads/pe_townhall_hcpcs_level.zip. Accessed November 18, 2006.
28. CPT 2005: Current Procedural Terminology. Professional Edition (2005), American Medical Association, Chicago
29. Centers for Medicare & Medicaid Services. Medicare coverage database. LMRP for ocular photodynamic therapy (OPT) with verteporfin (Visudyne) (L13561). Available at: http://www.cms.hhs.gov/mcd/viewlmrp.asp?lmrp_id=13561&lmrp_version=2&show=all. Accessed July 21, 2005.
30. Centers for Medicare and Medicaid Services. 2006 national physician fee schedule relative value file. Available at: http://www.cms.hhs.gov/PhysicianFeeSched. Accessed February 5, 2006.
31. Siegel J.E., Weinstein M.C., Russell L.B., et al. Recommendations for reporting cost-effectiveness analyses. JAMA 276 (1996) 1339-1341
32. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418
33. Brown G.C., Brown M.M., Sharma S., et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 107 (2000) 1374-1380
34. Genentech. Lucentis (ranibizumab). Available at: http://www.gene.com/gene/pipeline/status/vascular/amd/index.jsp?hl=en&ie=ISO-8859-1&q=lucentis. Accessed February 4, 2006.
35. GovTrack.us. 109th U.S. Congress. 1st session. H.R. 3617: Medicare Value-Based Purchasing for Physicians' Services Act of 2005. Available at: http://www.govtrack.us/data/us/bills.text/109/h3617.pdf. Accessed February 5, 2006.